General Information

General Information

DRAVP ID DRAVPe00443

Peptide Name IPB01(SARS-CoV-S (1151-1185),SR9, SARS-CoV-2-S (1169-1203))

Sequence ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL

Sequence Length 35

UniProt ID P59594 P0DTC2

Source Synthetic construct(derived from SARS-CoV-2 S protein)

Activity Information

Target Organism SARS-CoV-2,SARS-CoV,VSV

Assay cell fusion assay, single-cycle infection assay

Activity

[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.022±0.005 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=33.74±11.827 µM);
SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM);
Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).
[Ref.17942557]SARS-CoV:Inhibition of virus entry in VERO-E6 cells(EC50=0.005 µM).
[Ref.18442051]SARS-CoV: inhibition of PsV entry in Vero-E6 cells(EC50=0.34 µM).

Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity No cytotoxicity information found in the reference(s) presented

Binding Target membrane

Mechanism The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently.

Structure Information

PDB ID None

Predicted Structure Download No predicted structure available

Linear/Cyclic Linear

N-terminal Modification Free

C-terminal Modification Free

Other Modification None

Stereochemistry L

Physicochemical Information

Formula C168H287N47O58

Absent amino acids CFHMPTWY

Common amino acids ILN

Mass 3893.41

Pl 4.36

Basic residues 3

Acidic residues 6

Hydrophobic residues 15

Net charge -3

Boman Index -5930

Hydrophobicity -8.29

Aliphatic Index 142

Half Life

Mammalian:20 hour
Yeast:30 min
E.coli:>10 hour

Extinction Coefficient cystines 0

Absorbance 280nm 0

Polar residues 9

Literature Information

Literature 1

Title Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway.

Pubmed ID 17942557

Reference J Virol. 2008 Jan;82(1):588-92.

Author Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F.

DOI 10.1128/JVI.01697-07

Literature 2

Title Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.

Pubmed ID 18442051

Reference J Cell Biochem. 2008 Aug 15;104(6):2335-47.

Author Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM.

DOI 10.1002/jcb.21790

Literature 3

Title Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.

Pubmed ID 32376627

Reference J Virol. 2020 Jul 1;94(14):e00635-20.

Author Zhu Y, Yu D, Yan H, Chong H, He Y.

DOI 10.1128/JVI.00635-20